View Item 

Show simple item record

The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium
dc.contributor.authorSukul, Devraj
dc.contributor.authorSeth, Milan
dc.contributor.authorSchreiber, Theodore
dc.contributor.authorKhandelwal, Akshay
dc.contributor.authorCannon, Louis A.
dc.contributor.authorLaLonde, Thomas A.
dc.contributor.authorGurm, Hitinder S.
dc.date.accessioned2017-11-13T16:40:14Z
dc.date.available2019-01-07T18:34:38Zen
dc.date.issued2017-11-01
dc.identifier.citationSukul, Devraj; Seth, Milan; Schreiber, Theodore; Khandelwal, Akshay; Cannon, Louis A.; LaLonde, Thomas A.; Gurm, Hitinder S. (2017). "The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium." Catheterization and Cardiovascular Interventions 90(5): 724-732.
dc.identifier.issn1522-1946
dc.identifier.issn1522-726X
dc.identifier.urihttps://hdl.handle.net/2027.42/139064
dc.publisherWiley Periodicals, Inc.
dc.publisherR Foundation for Statistical Computing
dc.subject.otherpercutaneous coronary intervention
dc.subject.otherchronic kidney disease
dc.subject.otheranticoagulant
dc.subject.otherdialysis
dc.subject.otheroutcomes
dc.titleThe comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139064/1/ccd27001.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139064/2/ccd27001_am.pdf
dc.identifier.doi10.1002/ccd.27001
dc.identifier.sourceCatheterization and Cardiovascular Interventions
dc.identifier.citedreferenceNCDR CathPCI Registry v4.4 Coder’s Data Dictionary. Available at: https://www.ncdr.com/WebNCDR/docs/public-data-collection-documents/cathpci_v4_codersdictionary_4-4.pdf?sfvrsn=2. Accessed: July 28, 2016
dc.identifier.citedreferenceLincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE‐2 randomized trial. JAMA 2003; 289: 853 – 863.
dc.identifier.citedreferenceStone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218 – 2230.
dc.identifier.citedreferenceKastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688 – 696.
dc.identifier.citedreferenceKastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, et al. Abciximab and heparin versus bivalirudin for non‐ST‐elevation myocardial infarction. N Engl J Med 2011; 365: 1980 – 1989.
dc.identifier.citedreferenceStone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203 – 2216.
dc.identifier.citedreferenceHan Y, Guo J, Zheng Y, Zang H, Su X, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313: 1336 – 1346.
dc.identifier.citedreferenceSteg PG, van ‘t Hof A, Hamm CW, Clemmensen P, Lapostolle F, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207 – 2217.
dc.identifier.citedreferenceValgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015; 373: 997 – 1009.
dc.identifier.citedreferenceShahzad A, Kemp I, Mars C, Wilson K, Roome C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT‐PPCI): an open‐label, single centre, randomised controlled trial. Lancet 2014; 384: 1849 – 1858.
dc.identifier.citedreferencePerdoncin E, Seth M, Dixon S, Cannon L, Khandelwal A, et al. The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Eur Heart J 2016; 37: 1902 – 1909.
dc.identifier.citedreferenceDelhaye C, Maluenda G, Wakabayashi K, Ben‐Dor I, Collins SD, et al. Safety and in‐hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention. Am J Cardiol 2010; 105: 297 – 301.
dc.identifier.citedreferenceTsai TT, Maddox TM, Roe MT, Dai D, Alexander KP, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302: 2458 – 2464.
dc.identifier.citedreferenceKline‐Rogers E, Share D, Bondie D, Rogers B, Karavite D, et al. Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol 2002; 15: 387 – 392.
dc.identifier.citedreferenceMoscucci M, Rogers EK, Montoye C, Smith DE, Share D, et al. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation 2006; 113: 814 – 822.
dc.identifier.citedreferenceHansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Computat Graph Stat 2006; 15: 609 – 627.
dc.identifier.citedreferenceGu XS, Rosenbaum PR. Comparison of multivariate matching methods: Structures, distances, and algorithms. J Computat Graph Statist 1993; 2: 405 – 420.
dc.identifier.citedreferenceDevelopment Core Team R. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
dc.identifier.citedreferenceMehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, et al. Impact of chronic kidney disease on early (30‐day) and late (1‐year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv 2009; 2: 748 – 757.
dc.identifier.citedreferencePerdoncin E, Zhang M, Riba A, LaLonde TA, Grines CL, Gurm HS. Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Interv 2013; 6: 688 – 693.
dc.identifier.citedreferenceCavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: A meta‐analysis of randomised controlled trials. Lancet 2014; 384: 599 – 606.
dc.identifier.citedreferenceBriguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv 2015; 8: 414 – 423.
dc.identifier.citedreferenceAngiomax(R) (bivalirudin): Full Prescribing Information. Available at: http://www.angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf. Accessed: August 13, 2016
dc.identifier.citedreferenceAmin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, Kennedy K, Robertus K, Cohen DJ, Mahoney EM. Cost‐effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes 2010; 3: 358 – 365.
dc.identifier.citedreferenceShare DA, Campbell DA, Birkmeyer N, Prager RL, Gurm HS, Moscucci M, Udow‐Phillips M, Birkmeyer JD. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff (Millwood) 2011; 30: 636 – 645.
dc.identifier.citedreferenceMozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics‐2016 update: A report from the American Heart Association. Circulation 2016; 133: e38 – e360.
dc.identifier.citedreferenceCapodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012; 125: 2649 – 2661.
dc.identifier.citedreferenceKaw D, Malhotra D. Platelet dysfunction and end‐stage renal disease. Semin Dial 2006; 19: 317 – 322.
dc.identifier.citedreferenceBest PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR, Jr, Berger PB. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146: 345 – 350.
dc.identifier.citedreferenceBest PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113 – 1119.
dc.identifier.citedreferenceBonello L, De Labriolle A, Roy P, Steinberg DH, Okabe T, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol 2008; 102: 535 – 540.
dc.identifier.citedreferenceChew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM. Bivalirudin provides increasing benefit with decreasing renal function: A meta‐analysis of randomized trials. Am J Cardiol 2003; 92: 919 – 923.
dc.identifier.citedreferenceChew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ, Investigators R. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE‐2 trial). Am J Cardiol 2005; 95: 581 – 585.
dc.identifier.citedreferenceCharytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70: 2021 – 2030.
dc.identifier.citedreferenceCoca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377 – 1384.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ccd27001.pdf
Size:
355.1KB
Format:
PDF
View/Open
Name:
ccd27001_am.pdf
Size:
1.559MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.